免疫レパトアシーケンシング市場は、2025年の3億5,460万ドルから2030年までに5億6,050万ドルに成長し、予測期間中のCAGRは9.6%になると予想されます。IRS市場の主要企業には、Illumina, Inc.(米国)、Thermo Fisher Scientific Inc.(米国)、PacBio(米国)、Oxford Nanopore Technologies PLC(英国)、10X Genomics(米国)、Agilent Technologies(米国)、Danaher Corporation(米国)、タカラバイオ株式会社(日本)、Azenta US Inc.(米国)、Adaptive Biotechnologies(米国)、BGI Group(中国)、Personalis, Inc.(米国)、QIAGEN(オランダ)が含まれます。
目次
TABLE OF CONTENTS
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 SEGMENTS CONSIDERED & GEOGRAPHICAL SPREAD
1.3.2 INCLUSIONS & EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 STAKEHOLDERS
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 Key objectives of secondary research
2.1.2 PRIMARY DATA
2.1.2.1 Breakdown of primaries
2.1.2.2 Key objectives of primary research
2.2 MARKET ESTIMATION METHODOLOGY
2.2.1 GLOBAL MARKET ESTIMATION
2.2.1.1 Bottom-up approach
2.2.1.2 Insights from primary experts
2.2.2 SEGMENTAL MARKET ESTIMATION (TOP-DOWN APPROACH)
2.3 MARKET GROWTH RATE PROJECTION
2.4 DATA TRIANGULATION
2.5 STUDY ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.7 RISK ANALYSIS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 IMMUNE REPERTOIRE SEQUENCING MARKET OVERVIEW
4.2 NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT AND COUNTRY
4.3 IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET SHARE, BY TECHNOLOGY, 2025 VS. 2030
4.4 IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET SHARE, BY END USER, 2025
4.5 IMMUNE REPERTOIRE SEQUENCING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Increasing technological advancements
5.2.1.2 Growing focus on personalized/precision medicines
5.2.1.3 Increasing use of immune repertoire sequencing in organ transplant monitoring
5.2.1.4 Increasing applications in autoimmune disease research
5.2.1.5 Rising focus on cancer immunotherapy research
5.2.2 RESTRAINTS
5.2.2.1 Need for high capital investments
5.2.2.2 Limited clinical adoption and validation
5.2.3 OPPORTUNITIES
5.2.3.1 Integration of AI and ML into immune repertoire sequencing
5.2.3.2 Increasing applications in vaccine development
5.2.4 CHALLENGES
5.2.4.1 Variations in regulatory frameworks and international trade dynamics
5.2.4.2 Lack of workflow and data standardization
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
5.4 PRICING ANALYSIS
5.4.1 AVERAGE SELLING PRICE TREND OF IMMUNE REPERTOIRE SEQUENCING PRODUCTS, BY KEY PLAYER, 2022-2024
5.4.2 AVERAGE SELLING PRICE OF IMMUNE REPERTOIRE SEQUENCING INSTRUMENTS, BY REGION, 2024
5.5 SUPPLY CHAIN ANALYSIS
5.6 VALUE CHAIN ANALYSIS
5.7 ECOSYSTEM ANALYSIS
5.7.1 ROLE IN ECOSYSTEM
5.7.1.1 Product providers
5.7.1.2 Service providers
5.7.1.3 End users
5.7.1.4 Regulatory bodies
5.8 TECHNOLOGY ANALYSIS
5.8.1 KEY TECHNOLOGIES
5.8.1.1 High-throughput sequencing
5.8.1.2 Nanopore sequencing
5.8.1.3 Single-molecule real-time (SMRT) sequencing
5.8.2 COMPLEMENTARY TECHNOLOGIES
5.8.2.1 Bioinformatics and data analysis platforms
5.8.2.2 Multiplex PCR
5.8.2.3 5'RACE
5.8.3 ADJACENT TECHNOLOGIES
5.8.3.1 Multi-omics integration
5.8.3.2 Spatial genomics and transcriptomics
5.8.3.3 Single-cell sequencing technologies
5.9 PATENT ANALYSIS
5.10 TRADE DATA ANALYSIS
5.10.1 IMPORT DATA FOR HS CODE 3822, 2020-2024
5.10.2 EXPORT DATA FOR HS CODE 3822, 2020-2024
5.11 KEY CONFERENCES & EVENTS, 2025-2026
5.12 REGULATORY ANALYSIS
5.12.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.12.2 REGULATORY FRAMEWORK
5.12.2.1 North America
5.12.2.1.1 US
5.12.2.1.2 Canada
5.12.2.2 Europe
5.12.2.2.1 UK
5.12.2.3 Asia Pacific
5.12.2.3.1 China
5.12.2.3.2 Japan
5.12.2.3.3 South Korea
5.12.2.3.4 Australia
5.12.2.3.5 India
5.12.2.3.6 Rest of Asia Pacific
5.13 PORTER'S FIVE FORCES ANALYSIS
5.13.1 THREAT OF NEW ENTRANTS
5.13.2 THREAT OF SUBSTITUTES
5.13.3 BARGAINING POWER OF BUYERS
5.13.4 BARGAINING POWER OF SUPPLIERS
5.13.5 INTENSITY OF COMPETITIVE RIVALRY
5.14 KEY STAKEHOLDERS & BUYING CRITERIA
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.14.2 KEY BUYING CRITERIA
5.15 INVESTMENT & FUNDING SCENARIO
5.16 IMPACT OF AI/GEN AI ON IMMUNE REPERTOIRE SEQUENCING MARKET
6 IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT
6.1 INTRODUCTION
6.2 ASSAY KITS & REAGENTS
6.2.1 TCR KITS
6.2.1.1 Human TCR kits
6.2.1.1.1 Increased demand for high-throughput TCR profiling in oncology and immunotherapy research to fuel market growth
6.2.1.2 Mouse TCR kits
6.2.1.2.1 Rising demand for TCR profiling in preclinical studies and growing need for standardized workflows to drive segment
6.2.2 BCR KITS
6.2.2.1 Human BCR kits
6.2.2.1.1 Increasing demand for high-throughput profiling and rising focus on immunology research to fuel uptake
6.2.2.2 Mouse BCR kits
6.2.2.2.1 High demand for antibody discovery and preclinical research to boost segment growth
6.2.3 OTHER ASSAY KITS & REAGENTS
6.3 INSTRUMENTS & SOFTWARE
6.3.1 TECHNOLOGICAL ADVANCEMENTS IN TRANSLATIONAL RESEARCH AND COMPANION DIAGNOSTICS TO AUGMENT MARKET GROWTH
7 IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY
7.1 INTRODUCTION
7.2 SEQUENCING TECHNOLOGIES
7.2.1 BULK SEQUENCING (MULTI-CELL SEQUENCING) TECHNOLOGIES
7.2.1.1 Increasing adoption of TCR sequencing for inflammation-mediated diseases to support segment growth
7.2.2 SINGLE-CELL SEQUENCING TECHNOLOGIES
7.2.2.1 Need for integrative analysis of immune receptor repertoires and transcriptional states to spur market growth
7.3 LIBRARY PREPARATION TECHNOLOGIES
7.3.1 HIGH DEMAND FOR COST-EFFICIENT AND HIGH-THROUGHPUT IMMUNE REPERTOIRE PROFILING TO FUEL MARKET GROWTH
7.4 BIOINFORMATICS & DATA ANALYSIS TECHNOLOGIES
7.4.1 GROWING FOCUS ON RESEARCH TO DRIVE DEMAND FOR ADVANCED BIOINFORMATICS & DATA ANALYSIS TECHNOLOGIES
8 IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW
8.1 INTRODUCTION
8.2 SEQUENCING SERVICES
8.2.1 RISING NEED FOR HIGH-RESOLUTION IMMUNE PROFILING IN CANCER AND AUTOIMMUNE DISEASES TO DRIVE MARKET
8.3 DATA ANALYSIS SERVICES
8.3.1 HIGH DEMAND FOR STANDARDIZED NGS DATA INTERPRETATION AND CROSS-SAMPLE COMPARABILITY TO DRIVE MARKET
8.4 PRE-SEQUENCING SERVICES
8.4.1 INCREASED REQUIREMENT FOR STANDARDIZED WORKFLOWS FOR ADDRESSING PCR BIAS TO AUGMENT MARKET GROWTH
9 IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION
9.1 INTRODUCTION
9.2 RESEARCH APPLICATIONS
9.2.1 LOW SEQUENCING COSTS AND INCREASED NEED TO RESOLVE CELLULAR HETEROGENEITY AT HIGH RESOLUTION TO DRIVE MARKET
9.3 DRUG DISCOVERY & DEVELOPMENT
9.3.1 INCREASED NEED FOR TARGETED THERAPIES AND ADVANCEMENTS IN HIGH-THROUGHPUT SCREENING TO AID MARKET GROWTH
9.4 CLINICAL DIAGNOSTICS
9.4.1 GROWING DEMAND FOR EARLY DETECTION OF SUBCLINICAL CONDITIONS TO AID MARKET GROWTH
10 IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER
10.1 INTRODUCTION
10.2 ACADEMIC & RESEARCH INSTITUTES
10.2.1 INCREASED FUNDING FOR IMMUNOLOGICAL RESEARCH AND IMMUNOGENOMICS TO DRIVE MARKET
10.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
10.3.1 RISING FOCUS ON DRUG DISCOVERY AND THERAPEUTIC DEVELOPMENT TO SUPPORT MARKET GROWTH
10.4 OTHER END USERS
11 IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER
11.1 INTRODUCTION
11.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
11.2.1 NEED TO REDUCE IN-HOUSE INFRASTRUCTURE COSTS AND MEET SCALABILITY DEMANDS TO BOOST MARKET GROWTH
11.3 ACADEMIC & RESEARCH INSTITUTES
11.3.1 INCREASING FUNDING FOR GENOMIC RESEARCH AND GROWING DEMAND FOR COMPLEX DATA ANALYSIS TO AID MARKET GROWTH
11.4 OTHER END USERS
12 IMMUNE REPERTOIRE SEQUENCING MARKET, BY REGION
12.1 INTRODUCTION
12.2 NORTH AMERICA
12.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
12.2.2 US
12.2.2.1 US to dominate North American market during forecast period
12.2.3 CANADA
12.2.3.1 Presence of advanced research facilities and favorable government-funded genomic studies to spur market growth
12.3 EUROPE
12.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
12.3.2 GERMANY
12.3.2.1 Technological advancements in RNA sequencing to fuel market growth
12.3.3 UK
12.3.3.1 Increased cross-sector partnerships and advancements in AI tools for large sequencing datasets to boost market growth
12.3.4 FRANCE
12.3.4.1 Public-private collaborations and increased funding for advanced genomic infrastructure to aid market growth
12.3.5 ITALY
12.3.5.1 High investments in genomic research to drive market
12.3.6 SPAIN
12.3.6.1 Increased government investments in precision medicine, genomic medicine, and data science to propel market growth
12.3.7 REST OF EUROPE
12.4 ASIA PACIFIC
12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
12.4.2 CHINA
12.4.2.1 Rising incidence of chronic diseases and increasing collaborations among industry stakeholders to drive market
12.4.3 JAPAN
12.4.3.1 Increasing research on long-read and biomolecular sequencing to aid market growth
12.4.4 INDIA
12.4.4.1 Advancements in genomic research and focus on industry-academia collaborations to expedite market growth
12.4.5 SOUTH KOREA
12.4.5.1 Favorable government initiatives and investment in sequencing technologies to boost market growth
12.4.6 AUSTRALIA
12.4.6.1 Increased research funding and favorable government initiatives to drive market
12.4.7 REST OF ASIA PACIFIC
12.5 LATIN AMERICA
12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
12.5.2 BRAZIL
12.5.2.1 Supportive regulatory framework for biotechnology innovation to fuel market growth
12.5.3 MEXICO
12.5.3.1 High geriatric population and advancements in precision medicine research to support market growth
12.5.4 REST OF LATIN AMERICA
12.6 MIDDLE EAST
12.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
12.6.2 GCC COUNTRIES
12.6.2.1 Favorable government initiatives to drive drug development and clinical research
12.6.3 REST OF MIDDLE EAST
12.7 AFRICA
12.7.1 RISING GOVERNMENT FUNDING AND INCREASING INTERNATIONAL PARTNERSHIPS TO FAVOR MARKET GROWTH
12.7.2 MACROECONOMIC OUTLOOK FOR AFRICA
13 COMPETITIVE LANDSCAPE
13.1 INTRODUCTION
13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2022-2025
13.3 REVENUE ANALYSIS, 2022-2024
13.4 MARKET SHARE ANALYSIS, 2024
13.5 COMPANY VALUATION & FINANCIAL METRICS
13.5.1 COMPANY VALUATION
13.5.2 FINANCIAL METRICS
13.6 BRAND/PRODUCT COMPARISON
13.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
13.7.1 STARS
13.7.2 EMERGING LEADERS
13.7.3 PERVASIVE PLAYERS
13.7.4 PARTICIPANTS
13.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
13.7.5.1 Company footprint
13.7.5.2 Region footprint
13.7.5.3 Product and service footprint
13.7.5.4 Application footprint
13.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
13.8.1 PROGRESSIVE COMPANIES
13.8.2 RESPONSIVE COMPANIES
13.8.3 DYNAMIC COMPANIES
13.8.4 STARTING BLOCKS
13.8.5 COMPETITIVE BENCHMARKING
13.8.5.1 Detailed list of key startups/SMEs
13.8.5.2 Competitive benchmarking of key startups/SMEs
13.9 COMPETITIVE SCENARIO
13.9.1 PRODUCT LAUNCHES/APPROVALS/UPGRADES
13.9.2 DEALS
13.9.3 EXPANSIONS
14 COMPANY PROFILES
14.1 KEY PLAYERS
14.1.1 ILLUMINA, INC.
14.1.1.1 Business overview
14.1.1.2 Products/Services/Solutions offered
14.1.1.3 Recent developments
14.1.1.3.1 Product launches/approvals/upgrades
14.1.1.3.2 Deals
14.1.1.3.3 Expansions
14.1.1.4 MnM view
14.1.1.4.1 Key strengths
14.1.1.4.2 Strategic choices
14.1.1.4.3 Weaknesses & competitive threats
14.1.2 THERMO FISHER SCIENTIFIC INC.
14.1.2.1 Business overview
14.1.2.2 Products/Services/Solutions offered
14.1.2.3 Recent developments
14.1.2.3.1 Product launches/approvals/upgrades
14.1.2.3.2 Deals
14.1.2.3.3 Expansions
14.1.2.4 MnM view
14.1.2.4.1 Key strengths
14.1.2.4.2 Strategic choices
14.1.2.4.3 Weaknesses & competitive threats
14.1.3 PACBIO
14.1.3.1 Business overview
14.1.3.2 Products/Services/Solutions offered
14.1.3.3 Recent developments
14.1.3.3.1 Product launches/approvals/upgrades
14.1.3.3.2 Deals
14.1.3.3.3 Expansions
14.1.3.4 MnM view
14.1.3.4.1 Key strengths
14.1.3.4.2 Strategic choices
14.1.3.4.3 Weaknesses & competitive threats
14.1.4 OXFORD NANOPORE TECHNOLOGIES PLC
14.1.4.1 Business overview
14.1.4.2 Products/Services/Solutions offered
14.1.4.3 Recent developments
14.1.4.3.1 Product launches/approvals/upgrades
14.1.4.3.2 Deals
14.1.4.4 MnM view
14.1.4.4.1 Key strengths
14.1.4.4.2 Strategic choices
14.1.4.4.3 Weaknesses & competitive threats
14.1.5 10X GENOMICS
14.1.5.1 Business overview
14.1.5.2 Products/Services/Solutions offered
14.1.5.3 Recent developments
14.1.5.3.1 Product launches/approvals/upgrades
14.1.5.4 MnM view
14.1.5.4.1 Key strengths
14.1.5.4.2 Strategic choices
14.1.5.4.3 Weaknesses & competitive threats
14.1.6 QIAGEN
14.1.6.1 Business overview
14.1.6.2 Products/Services/Solutions offered
14.1.6.3 Recent developments
14.1.6.3.1 Product launches/approvals/upgrades
14.1.6.3.2 Deals
14.1.6.3.3 Expansions
14.1.7 AGILENT TECHNOLOGIES
14.1.7.1 Business overview
14.1.7.2 Products/Services/Solutions offered
14.1.7.3 Recent developments
14.1.7.3.1 Deals
14.1.7.3.2 Expansions
14.1.8 DANAHER CORPORATION
14.1.8.1 Business overview
14.1.8.2 Products/Services/Solutions offered
14.1.8.3 Recent developments
14.1.8.3.1 Deals
14.1.9 TAKARA BIO INC.
14.1.9.1 Business overview
14.1.9.2 Products/Services/Solutions offered
14.1.9.3 Recent developments
14.1.9.3.1 Deals
14.1.10 ADAPTIVE BIOTECHNOLOGIES
14.1.10.1 Business overview
14.1.10.2 Products/Services/Solutions offered
14.1.11 BGI GROUP
14.1.11.1 Business overview
14.1.11.2 Products/Services/Solutions offered
14.1.11.3 Recent developments
14.1.11.3.1 Product launches/approvals/upgrades
14.1.11.3.2 Deals
14.1.11.3.3 Other developments
14.1.12 TECAN TRADING AG
14.1.12.1 Business overview
14.1.12.2 Products/Services/Solutions offered
14.1.12.3 Recent developments
14.1.12.3.1 Deals
14.1.13 AZENTA US INC.
14.1.13.1 Business overview
14.1.13.2 Products/Services/Solutions offered
14.1.14 PERSONALIS, INC.
14.1.14.1 Business overview
14.1.14.2 Products/Services/Solutions offered
14.1.14.3 Recent developments
14.1.14.3.1 Deals
14.1.14.3.2 Other developments
14.1.15 CREATIVE BIOLABS
14.1.15.1 Business overview
14.1.15.2 Products/Services/Solutions offered
14.2 OTHER PLAYERS
14.2.1 CELEMICS, INC.
14.2.2 CELLCARTA
14.2.3 IREPERTOIRE, INC.
14.2.4 NEW ENGLAND BIOLABS
14.2.5 CERBA RESEARCH
14.2.6 CEGAT GMBH
14.2.7 ELEMENT BIOSCIENCES
14.2.8 SEQALIS
14.2.9 SYNBIO TECHNOLOGIES
14.2.10 MEDGENOME
14.2.11 ENPICOM
15 APPENDIX
15.1 DISCUSSION GUIDE
15.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
15.3 CUSTOMIZATION OPTIONS
15.4 RELATED REPORTS
15.5 AUTHOR DETAILS
